FDA 510(k) Premarket Notification — Class I/II Device Clearance
Record ID: biomedical-reg-002 (Biomedical · regulation · license) Issuing body / enforcer: U.S. Food and Drug Administration (FDA), CDRH Jurisdiction: United States
1. What it is
The 510(k) is a premarket notification under section 510(k) of the Federal Food, Drug, and Cosmetic Act. Engineers must internalize the critical distinction: a 510(k) results in a clearance, not an approval. FDA does not determine that the device is safe and effective in the PMA sense — it determines that the device is substantially equivalent to a legally marketed predicate device.
It is the workhorse U.S. market pathway: the majority of Class II devices (and some Class I devices requiring premarket notification) reach market this way. It is faster and cheaper than PMA but entirely dependent on the existence of a suitable predicate.
2. Scope and who it applies to
- Applies to Class I and Class II devices for which FDA requires premarket notification (most Class I devices are 510(k)-exempt; check the classification database).
- Trigger: Before introducing a device into interstate commerce, the manufacturer (or U.S. agent/importer) must submit the 510(k) and receive FDA's "substantially equivalent" letter — marketing before clearance is a prohibited act.
- When a new 510(k) is needed: For a new device, and for changes to a cleared device that could significantly affect safety/effectiveness or constitute a major change in intended use (FDA's "when to submit" guidance — the "510(k) modifications" guidances — govern this decision; the "could significantly affect" judgment is one of the most litigated gray areas in device regulatory practice).
3. Key requirements and compliance obligations
- Substantial equivalence: The submitter must identify a predicate device (legally marketed in the U.S. — a 510(k)-cleared, PMA-approved, or pre-amendments device) and demonstrate the new device has the same intended use and either the same technological characteristics, or different characteristics that do not raise different questions of safety and effectiveness (supported by performance data).
- Predicate strategy is engineering strategy: Choosing a predicate with a clean recall history matters — a predicate with design-related recalls invites reviewers and inspectors to probe whether your risk management file (now under QMSR/ISO 13485) and design inputs absorbed the lessons of that recall.
- Submission content: Device description, intended use/indications, technological comparison to predicate(s), performance testing (bench, animal, and clinical where needed), software documentation (per FDA software guidance, commensurate with documentation level), biocompatibility (ISO 10993), sterility/shelf-life validation, EMC/electrical safety (IEC 60601 series), labeling, and a truthful-and-accurate statement.
- Review mechanics: FDA's target is 90 FDA days (clock stops during sponsor holds — "FDA days" excludes time the submission sits with the sponsor answering questions). Interactive review is common; Additional Information (AI) requests pause the clock.
- De Novo pathway: For novel low-to-moderate-risk devices with no predicate — a separate classification route (not a 510(k)), with a ~150-day review goal. Successful De Novo creates a new classification regulation that future 510(k)s can predicate on.
- User fees (FY 2026, catalogue-verified): Standard 510(k) fee $26,067 (small-business discounts apply; verify current fee at fda.gov before budgeting — MDUFA fees adjust annually).
- QMSR interaction: 510(k) clearance is generally not conditioned on a pre-clearance QMS inspection, but QMSR compliance is enforced on its own track (inspections, 483s, Warning Letters) — see shared brief
fda-qmsr-21-cfr-820.md.
4. Penalties and consequences of non-compliance
- Marketing without required clearance = adulterated and misbranded device; FDA enforcement tools include Warning Letters, seizure, injunction, import detention, and criminal prosecution for knowing violations.
- Misbranding by reference: Promoting a 510(k)-cleared device for uncleared indications (off-label promotion by the manufacturer) is a misbranding violation — engineers writing marketing copy or app-store descriptions need to know the cleared indications boundary.
- Predicate-related fraud (e.g., "predicate creep" — incremental changes across generations drifting from the original predicate's safety profile) draws FDA scrutiny and can support enforcement where submissions were misleading.
5. Version and live changes — verified
- The 510(k) program is statutory (FD&C Act §510(k)); no structural overhaul is in effect as of September 2026.
- FY 2026 user fee: $26,067 standard 510(k) (catalogue-verified; confirm at fda.gov — fees reset each fiscal year on October 1).
- FDA's eSTAR electronic submission template is now the standard submission format — incomplete eSTAR submissions are rejected at acceptance review.
- Flag: FDA periodically updates software, biocompatibility, and cybersecurity documentation expectations via guidance; the submission-content expectations described here should be re-verified against current guidance before drafting.
6. Related certifications (Biomedical)
From the catalogue (record_type=certification, importance=license/flagship, Biomedical):
- RAC-Devices (RAPS) — the 510(k)/substantial-equivalence framework is core exam content; RAC holders typically own submission strategy.
- CCE — tangential (clinical engineering, not premarket submissions).
- PE — no biomedical PE exam; not tested.
7. Honest flags
- Fee and timeline figures are catalogue-verified for FY 2026; both change (fees annually, review times with MDUFA reauthorization). Always confirm at fda.gov before project planning.
- This brief is an orientation, not submission advice — the "when to submit a new 510(k) for a change" decision is fact-specific and guidance-driven.
Original ETS reference writing, verified against public sources on 2026-09-30. Thin sourcing is flagged inline. Not legal advice — confirm current editions with the issuing body.